
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Laryngopharyngeal Reflux (LPR): A Consensus-Based Clinical Mind Map</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Laryngopharyngeal Reflux (LPR): A Consensus-Based Clinical Mind Map</strong></summary>
            <div>
                <ul><li>- This mind map synthesizes and compares key findings from two major international consensus statements:</li><li>- <b>The San Diego Consensus</b> for Laryngopharyngeal Symptoms and Laryngopharyngeal Reflux Disease (Am J Gastroenterol 2025)</li><li>- <b>The Dubai Definition and Diagnostic Criteria</b> of Laryngopharyngeal Reflux: The IFOS Consensus (Laryngoscope 2023)</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- 1. What is the minimum number of hypopharyngeal reflux events in 24h on HEMII-pH testing that suggests a diagnosis of LPR according to the Dubai Consensus?</li><li>- 2. The San Diego Consensus recommends a trial of twice-daily PPI for how long to assess symptomatic response in LPS with esophageal symptoms?</li><li>- 3. According to the San Diego Consensus, what percentage of esophageal acid exposure time (AET) on all 4 days of a 96-hr wireless pH study predicts a low likelihood of response to antisecretory therapy?</li><li>- 4. The Dubai Consensus states that erosive esophagitis is found in what percentage range of LPR patients?</li><li>- 5. The San Diego Consensus highlights a tool called LCAT for identifying what specific psychological processes in patients with LPS?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>I. Terminology & Definitions: A Tale of Two Paradigms</strong></summary>
            <div>
                <ul><li>- A fundamental difference exists between the two consensus groups on how to define and label the condition, which impacts the entire clinical approach.</li></ul>
                
        <details>
            <summary><strong>San Diego Consensus: Differentiating Symptoms (LPS) from Disease (LPRD)</strong></summary>
            <div>
                <ul><li>- Proposes a major terminology shift to avoid assuming reflux is the cause based on symptoms alone.</li><li>- <b>CRITICAL POINT</b>: The presence of LPS does <u>not</u> equate to LPRD.</li></ul>
                
        <details>
            <summary><strong><u>Laryngopharyngeal Symptoms (LPS)</u></strong></summary>
            <div>
                <ul><li>- Refers to the chronic and frequent throat/airway symptoms themselves.</li><li>- This term is descriptive and does <u>not</u> implicate reflux as the etiology.</li><li>- Criteria: Symptoms must be frequent (at least <q>twice weekly</q>) and chronic (present for <q>more than 8 weeks</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><u>Laryngopharyngeal Reflux Disease (LPRD)</u></strong></summary>
            <div>
                <ul><li>- A specific diagnosis requiring two components:</li><li>- 1. Presence of chronic, troublesome LPS.</li><li>- 2. <b>Objective evidence</b> supporting a relationship between symptoms and gastroesophageal reflux.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dubai Consensus: A Unified, Broader Definition of LPR</strong></summary>
            <div>
                <ul><li>- Maintains the traditional term 'Laryngopharyngeal Reflux (LPR)' but provides a formal definition.</li><li>- Defines LPR as a <u>disease</u> of the upper aerodigestive tract resulting from direct and/or indirect effects of gastroduodenal content reflux.</li><li>- This reflux induces <b>morphological</b> and/or <b>neurological</b> changes in the upper aerodigestive tract.</li></ul>
                
        <details>
            <summary><strong>Alternative Names</strong></summary>
            <div>
                <ul><li>- Acknowledges many alternative names used in practice:</li><li>- Silent reflux, pharyngolaryngeal reflux, extraesophageal reflux, atypical GERD, reflux laryngitis.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Areas of Consensus in Pathophysiology</strong></summary>
            <div>
                <ul><li>- Both groups agree that LPR/LPS involves more than just acid and has a complex pathophysiology.</li></ul>
                
        <details>
            <summary><strong>Shared Mechanisms</strong></summary>
            <div>
                <ul><li>- LPR and GERD share common mechanisms (e.g., LES dysfunction) but can present with different clinical pictures.</li><li>- Dubai: Highlights the role of <b>pepsin</b> and <b>bile salts</b> in causing mucosal inflammation and tissue changes.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Contributing Factors</strong></summary>
            <div>
                <ul><li>- Dubai Consensus identifies factors that may impair gastroesophageal function:</li><li>- <b>Tobacco use</b>, <b>obesity</b>, primary esophageal dysmotility.</li><li>- Diets high in fat, salt, sugar, mint, or acidic content.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>II. Clinical Presentation: Symptoms & Signs</strong></summary>
            <div>
                <ul><li>- There is broad agreement on the common symptoms and the limitations of physical signs.</li></ul>
                
        <details>
            <summary><strong>Symptoms (Broad Consensus)</strong></summary>
            <div>
                <ul><li>- Both panels agree on a core set of <u>non-specific</u> symptoms.</li></ul>
                
        <details>
            <summary><strong>Core Laryngopharyngeal Symptoms</strong></summary>
            <div>
                <ul><li>- <b>Cough</b> (chronic, troublesome)</li><li>- <b>Voice change</b> / hoarseness</li><li>- <b>Throat clearing</b></li><li>- Excess throat <b>phlegm</b> / sticky mucus</li><li>- <b>Throat pain</b> / sore throat</li><li>- <b>Globus sensation</b></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Associated Esophageal Symptoms</strong></summary>
            <div>
                <ul><li>- Both panels recognize that typical GERD symptoms can be present.</li><li>- Heartburn, regurgitation, chest pain.</li><li>- San Diego: Emphasizes that assessing for these is a critical first step in patient stratification.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Signs on Laryngoscopy (Strong Consensus on Limitations)</strong></summary>
            <div>
                <ul><li>- <b><u>CRITICAL CONSENSUS</u></b>: Laryngoscopic findings are neither specific nor pathognomonic for LPR/LPRD.</li><li>- A diagnosis <u>CANNOT</u> be made based on laryngoscopy findings alone.</li></ul>
                
        <details>
            <summary><strong>Primary Role of Laryngoscopy</strong></summary>
            <div>
                <ul><li>- The main purpose is to evaluate for other non-reflux related causes of symptoms.</li><li>- Most importantly: to rule out <b>malignancy</b>.</li><li>- San Diego: Recommends <u>videostroboscopy</u> for hoarseness if white-light exam is unrevealing.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Common (but Non-Specific) Signs</strong></summary>
            <div>
                <ul><li>- Arytenoid erythema and edema</li><li>- Posterior commissure hypertrophy (pachydermia)</li><li>- Diffuse laryngeal erythema</li><li>- Vocal fold edema</li><li>- Subglottic edema ('pseudosulcus')</li><li>- Endolaryngeal mucus</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Scoring Systems (Consensus: Not for Diagnosis)</strong></summary>
            <div>
                <ul><li>- Both panels agree that scoring systems based on laryngeal findings are not diagnostic.</li><li>- San Diego: Specifically states the <b>Reflux Finding Score (RFS)</b> and <b>Reflux Sign Assessment (RSA)</b> are not diagnostic of LPRD.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Vocal Process Granuloma</strong></summary>
            <div>
                <ul><li>- Dubai: Can be a sign of LPR and should prompt evaluation or treatment.</li><li>- San Diego: Notes uncertainty, citing a survey where laryngologists considered <b>phonotrauma</b> (<q>88%</q>) a more likely cause than reflux (<q>67%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>III. Diagnostic Pathway & Objective Testing</strong></summary>
            <div>
                <ul><li>- This is an area with significant differences in recommended approaches, particularly regarding initial strategy and choice of reflux monitoring.</li></ul>
                
        <details>
            <summary><strong>Initial Patient Stratification (San Diego Emphasis)</strong></summary>
            <div>
                <ul><li>- A key unique contribution of the San Diego consensus is the initial branching of the care pathway.</li></ul>
                
        <details>
            <summary><strong><b>Step 1:</b> Assess for Esophageal Symptoms</strong></summary>
            <div>
                <ul><li>- <u>Crucial First Step</u>: Categorize patients into two groups:</li><li>- 1. LPS <b>with</b> concurrent esophageal symptoms (heartburn, regurgitation).</li><li>- 2. <b>Isolated</b> LPS (no esophageal symptoms).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Empiric Therapeutic Trial (Divergent Recommendations)</strong></summary>
            <div>
                <ul><li>- The role and timing of a medication trial differ between the two guidelines.</li></ul>
                
        <details>
            <summary><strong>San Diego Recommendation</strong></summary>
            <div>
                <ul><li>- An empiric trial is appropriate <u>only</u> for patients with <b>LPS + concurrent esophageal symptoms</b>.</li><li>- For <u>isolated LPS</u>, objective reflux testing is recommended <u>before</u> empiric trials to personalize management.</li><li>- Trial Regimen: <b>Twice-daily PPI</b> for <q>3 months</q>, with or without alginate therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dubai Recommendation</strong></summary>
            <div>
                <ul><li>- An empiric trial is an option if HEMII-pH testing is unavailable.</li><li>- The trial should cover acid, weakly acid, and non-acid reflux.</li><li>- Success is based on symptom improvement at <q>3 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Objective Reflux Monitoring (The Reference Standard)</strong></summary>
            <div>
                <ul><li>- <b>CONSENSUS</b>: Objective testing is the reference standard for diagnosis and is <u>required</u> before considering invasive anti-reflux management (e.g., surgery).</li><li>- Testing should be performed <b>OFF</b> acid suppression therapy (washout period of at least <q>7 days</q>).</li></ul>
                
        <details>
            <summary><strong>pH-Impedance Monitoring</strong></summary>
            <div>
                <ul><li>- Measures both acid (pH drop) and non-acid (impedance change) reflux events, providing mechanistic detail.</li></ul>
                
        <details>
            <summary><strong>Dubai Consensus: <u>HEMII-pH</u> as the Preferred Tool</strong></summary>
            <div>
                <ul><li>- <b>Hypopharyngeal-esophageal multichannel intraluminal impedance-pH (HEMII-pH)</b> is highlighted as the key objective tool.</li><li>- Diagnostic Criterion: <q><b>>1</b> hypopharyngeal reflux event</q> (acid, weakly acid, or non-acid) in 24 hours.</li><li>- Emphasizes that standard esophageal-only or dual pH probes are <u>inadequate</u> for diagnosing LPR.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>San Diego Consensus: Role of pH-Impedance</strong></summary>
            <div>
                <ul><li>- Acknowledged as a diagnostic option, particularly useful in <u>isolated LPS</u> to understand mechanisms.</li><li>- Notes it has a lower diagnostic yield for GERD compared to prolonged wireless pH monitoring.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prolonged Wireless pH Monitoring (96-hour)</strong></summary>
            <div>
                <ul><li>- A key focus of the San Diego Consensus, not emphasized by the Dubai group.</li></ul>
                
        <details>
            <summary><strong>San Diego Recommendation</strong></summary>
            <div>
                <ul><li>- Preferred test for unproven GERD, especially in patients with concomitant esophageal symptoms and before escalating management.</li><li>- Major Advantage: Captures day-to-day variability in acid exposure.</li></ul>
                
        <details>
            <summary><strong>Key Diagnostic Thresholds (AET)</strong></summary>
            <div>
                <ul><li>- <b>Proven GERD</b>: Distal esophageal Acid Exposure Time (AET) <q><b>>6.0%</b></q>.</li><li>- <b>Physiologic Reflux</b>: AET <q><b><4.0%</b></q> on <u>all 4 days</u> of the study predicts a low likelihood of symptom response to antisecretory therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Testing Modalities (Consensus: Limited/No Role)</strong></summary>
            <div>
                <ul><li>- <b>Oropharyngeal pH monitoring (e.g., Restech)</b>: Both panels agree this has <u>poor specificity</u> and is not recommended as a standalone diagnostic tool.</li><li>- <b>Pepsin Saliva Detection</b>: Dubai consensus notes it's a non-invasive adjunctive test but cannot confirm LPR and has many limitations (diet, timing, low sensitivity). Not discussed by San Diego.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Upper GI Endoscopy (Broad Consensus)</strong></summary>
            <div>
                <ul><li>- <b>CONSENSUS</b>: Endoscopy may be normal in many patients with LPR/LPS.</li><li>- Its findings can provide conclusive or supportive evidence of underlying GERD.</li></ul>
                
        <details>
            <summary><strong>Conclusive Evidence of GERD</strong></summary>
            <div>
                <ul><li>- San Diego: Los Angeles (LA) grades <q>B, C, or D erosive esophagitis</q> and/or biopsy-proven <q>Barrett's esophagus</q>.</li><li>- Dubai: Notes erosive esophagitis is found in only <q>10%-30%</q> of LPR patients.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Indications for Endoscopy</strong></summary>
            <div>
                <ul><li>- <b>CONSENSUS</b>: Indicated for <u>alarm symptoms</u> (severe dysphagia, weight loss, hematemesis, family history of upper GI cancer).</li><li>- Also indicated for patients who do not respond to an empiric therapeutic trial.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Esophageal Manometry (Niche Role)</strong></summary>
            <div>
                <ul><li>- Dubai Consensus: Indicated to evaluate for esophageal dysmotility or to assist in reflux probe placement in non-responders.</li><li>- Not recommended as a primary diagnostic tool for LPR.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>IV. Beyond Reflux: The Brain-Larynx Axis (San Diego Emphasis)</strong></summary>
            <div>
                <ul><li>- A major focus of the San Diego Consensus, highlighting that symptoms are often driven by factors other than or in addition to reflux.</li></ul>
                
        <details>
            <summary><strong>Laryngeal Hyperresponse & Hypervigilance</strong></summary>
            <div>
                <ul><li>- These behavioral and psychological processes can be the primary etiology of LPS or contribute to symptoms in confirmed LPRD.</li></ul>
                
        <details>
            <summary><strong>Definitions</strong></summary>
            <div>
                <ul><li>- <u>Laryngeal Hyperresponse</u>: Repetitive behaviors like throat clearing, coughing, or biomechanical strain.</li><li>- <u>Laryngeal Hypervigilance</u>: Increased threat-induced attention to the larynx, often co-existing with symptom-specific anxiety.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Identification Tool: LCAT</strong></summary>
            <div>
                <ul><li>- The <b>Laryngeal Cognitive-Affective Tool (LCAT)</b> is a validated patient-reported outcome instrument.</li><li>- Helps identify individuals with elevated levels of <q>hypervigilance and anxiety</q> related to their LPS who may benefit from behavioral intervention.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment for Brain-Larynx Dysfunction</strong></summary>
            <div>
                <ul><li>- Recommended for:</li><li>- Patients with <u>isolated LPS</u> and negative reflux testing.</li><li>- Patients with confirmed LPRD who have a partial or poor response to anti-reflux therapy.</li></ul>
                
        <details>
            <summary><strong>Laryngeal Recalibration Therapy (LRT)</strong></summary>
            <div>
                <ul><li>- A structured behavioral therapy provided by a voice-specialized <b>Speech-Language Pathologist (SLP)</b>.</li><li>- Integrates traditional voice therapy techniques with autonomic regulation (heart rate variability biofeedback) and cognitive reframing (acceptance and commitment therapy).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pharmacologic Neuromodulation</strong></summary>
            <div>
                <ul><li>- Aims to improve laryngeal hypersensitivity.</li></ul>
                
        <details>
            <summary><strong>Gabapentin / Pregabalin</strong></summary>
            <div>
                <ul><li>- May be an effective adjunct to LRT, especially for <b>cough</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Tricyclic Antidepressants (TCAs)</strong></summary>
            <div>
                <ul><li>- May help LPS symptoms, but must monitor for anticholinergic side effects like <b>xerostomia</b> (dry mouth).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>SSRIs / SNRIs</strong></summary>
            <div>
                <ul><li>- Not specifically studied in LPS, but may benefit individuals with concomitant clinical anxiety and/or depression.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>V. Patient-Reported Outcome (PRO) Instruments</strong></summary>
            <div>
                <ul><li>- <b><u>STRONG CONSENSUS</u></b>: PROs are valuable for tracking symptom severity and treatment response over time, but they are <u>NOT for diagnosis</u> due to their non-specificity.</li></ul>
                
        <details>
            <summary><strong>LPR-Specific PROs</strong></summary>
            <div>
                <ul><li>- Instruments like the <b>Reflux Symptom Index (RSI)</b> and <b>Reflux Symptom Score (RSS)</b> are non-specific for diagnosing LPR/LPRD.</li><li>- San Diego: A clinically significant RSI cutoff of <q>≥13</q> could not distinguish patients with increased proximal reflux on objective testing.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>GERD-Specific PROs</strong></summary>
            <div>
                <ul><li>- Instruments like GERDQ and GERD-HRQL are useful for assessing esophageal symptoms but are not specific for LPS and LPRD.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
